Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group.

Autor: Costa Rivas M; Department of Medical Oncology, Complexo Hospitalario Universitario de Vigo, Clara Campoamor 341, 36312, Vigo, Spain., Huidobro Vence G; Department of Medical Oncology, Complexo Hospitalario Universitario de Vigo, Clara Campoamor 341, 36312, Vigo, Spain., Fírvida Pérez JL; Department of Medical Oncology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain., Campos Balea B; Department of Medical Oncology, Hospital Universitario Lucus Augusti de Lugo, Lugo, Spain., García Gonzalez J; Department of Medical Oncology, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain., Lázaro Quintela M; Department of Medical Oncology, Complexo Hospitalario Universitario de Vigo, Clara Campoamor 341, 36312, Vigo, Spain., Caeiro Muñoz M; Department of Radiation Oncology, Complexo Hospitalario Universitario de Vigo, Vigo, Spain., Taboada Valladares B; Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain., Castro Gómez JE; Department of Radiation Oncology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain., Vázquez Estevez S; Department of Medical Oncology, Hospital Universitario Lucus Augusti de Lugo, Lugo, Spain., Afonso Afonso FJ; Department of Medical Oncology, Complexo Hospitalario Universitario de Ferrol, Ferrol, Spain., Azpitarte Raposeiras C; Department of Medical Oncology, Complexo Hospitalario de Pontevedra, Pontevedra, Spain., Amenedo Gancedo M; Department of Medical Oncology, Centro Oncológico de Galicia, A Coruña, Spain., Casal Rubio J; Department of Medical Oncology, Complexo Hospitalario Universitario de Vigo, Clara Campoamor 341, 36312, Vigo, Spain. joaquin.casal.rubio@sergas.es.
Jazyk: angličtina
Zdroj: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2018 Nov; Vol. 20 (11), pp. 1467-1473. Date of Electronic Publication: 2018 Apr 25.
DOI: 10.1007/s12094-018-1880-x
Abstrakt: Purpose: The aim of this phase II study was to evaluate the activity and safety of the combination of cisplatin and vinorelbine with thoracic radiotherapy in unresectable locally advanced stage III non-small cell lung cancer (NSCLC). The primary endpoint was the objective response rate (ORR). Secondary objectives included toxicity profile, progression-free survival (PFS), and overall survival (OS).
Materials and Methods: A total of 48 NSCLC patients were enrolled (median age 60 years, 52% stage IIIA and 48% stage IIIB, 52% adenocarcinoma). Patients received three cycles of chemotherapy every 21 days [intravenous cisplatin 80 mg/m 2 and intravenous vinorelbine 25 mg/m 2 on day 1 and oral vinorelbine on day 8 (60 mg/m 2 )] concurrent with radiotherapy (66 Gy, administered at 1.8 Gy per day, five consecutive days per week).
Results: ORR was 79.2% (72.9% showing partial response and 6.3% showing complete response). With a median follow-up of 20.7 months, median PFS was 12 months and median OS was 36 months. Grade 3/4 toxicities were: neutropenia (14.5%), anaemia (6.2%), vomiting (2%), and oesophagitis (4.2%). No toxic deaths were reported.
Conclusion: This combined regimen shows efficacy and a manageable safety profile. PFS and OS outcomes are encouraging and warrant further research.
Databáze: MEDLINE
Externí odkaz: